Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Persons with epilepsy (PWE) have a higher risk of developing depressive disorders (DDs), and people with primary DD have an increased risk of developing epilepsy. Furthermore, a lifetime history of DD has been associated with a worse response of the seizure disorder to pharmacotherapy and epilepsy surgery. The first part of this article reviews the literature of this problem with the intention of highlighting the neurobiologic pathogenic mechanisms operant in DD with a potential to facilitate the epileptogenic process and/or cortical hyperexcitability in humans and experimental animal studies of depression. They include the following: (i) a hyperactive hypothalamic-pituitary-adrenal axis and the associated structural and functional abnormalities of limbic structures, (ii) increased glutamatergic activity and decreased GABAergic and serotonergic activity, and (iii) immunologic disturbances. In the second part of this article, we suggest research strategies to test the hypothesis of whether depression worsens the course of epilepsy and identify the pathogenic mechanisms operant in this process. This article is part of a Special Issue entitled "NEWroscience 2013".

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalEpilepsy and Behavior
Volume38
DOIs
StatePublished - Sep 1 2014

Fingerprint

Epilepsy
Depressive Disorder
Depression
Research
Therapeutics
Drug Therapy

Keywords

  • 1β-Interleukin
  • Gamma-aminobutyric acid
  • Glutamate
  • Hippocampal atrophy
  • Hypothalamic-pituitary-adrenal hyperactivity
  • Major depressive disorder
  • Serotonin

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

@article{3b410a6d2a5a4d6492840bf189cc51e0,
title = "Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question",
abstract = "Persons with epilepsy (PWE) have a higher risk of developing depressive disorders (DDs), and people with primary DD have an increased risk of developing epilepsy. Furthermore, a lifetime history of DD has been associated with a worse response of the seizure disorder to pharmacotherapy and epilepsy surgery. The first part of this article reviews the literature of this problem with the intention of highlighting the neurobiologic pathogenic mechanisms operant in DD with a potential to facilitate the epileptogenic process and/or cortical hyperexcitability in humans and experimental animal studies of depression. They include the following: (i) a hyperactive hypothalamic-pituitary-adrenal axis and the associated structural and functional abnormalities of limbic structures, (ii) increased glutamatergic activity and decreased GABAergic and serotonergic activity, and (iii) immunologic disturbances. In the second part of this article, we suggest research strategies to test the hypothesis of whether depression worsens the course of epilepsy and identify the pathogenic mechanisms operant in this process. This article is part of a Special Issue entitled {"}NEWroscience 2013{"}.",
keywords = "1β-Interleukin, Gamma-aminobutyric acid, Glutamate, Hippocampal atrophy, Hypothalamic-pituitary-adrenal hyperactivity, Major depressive disorder, Serotonin",
author = "Kanner, {Andres M}",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.yebeh.2014.06.027",
language = "English (US)",
volume = "38",
pages = "3--7",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question

AU - Kanner, Andres M

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Persons with epilepsy (PWE) have a higher risk of developing depressive disorders (DDs), and people with primary DD have an increased risk of developing epilepsy. Furthermore, a lifetime history of DD has been associated with a worse response of the seizure disorder to pharmacotherapy and epilepsy surgery. The first part of this article reviews the literature of this problem with the intention of highlighting the neurobiologic pathogenic mechanisms operant in DD with a potential to facilitate the epileptogenic process and/or cortical hyperexcitability in humans and experimental animal studies of depression. They include the following: (i) a hyperactive hypothalamic-pituitary-adrenal axis and the associated structural and functional abnormalities of limbic structures, (ii) increased glutamatergic activity and decreased GABAergic and serotonergic activity, and (iii) immunologic disturbances. In the second part of this article, we suggest research strategies to test the hypothesis of whether depression worsens the course of epilepsy and identify the pathogenic mechanisms operant in this process. This article is part of a Special Issue entitled "NEWroscience 2013".

AB - Persons with epilepsy (PWE) have a higher risk of developing depressive disorders (DDs), and people with primary DD have an increased risk of developing epilepsy. Furthermore, a lifetime history of DD has been associated with a worse response of the seizure disorder to pharmacotherapy and epilepsy surgery. The first part of this article reviews the literature of this problem with the intention of highlighting the neurobiologic pathogenic mechanisms operant in DD with a potential to facilitate the epileptogenic process and/or cortical hyperexcitability in humans and experimental animal studies of depression. They include the following: (i) a hyperactive hypothalamic-pituitary-adrenal axis and the associated structural and functional abnormalities of limbic structures, (ii) increased glutamatergic activity and decreased GABAergic and serotonergic activity, and (iii) immunologic disturbances. In the second part of this article, we suggest research strategies to test the hypothesis of whether depression worsens the course of epilepsy and identify the pathogenic mechanisms operant in this process. This article is part of a Special Issue entitled "NEWroscience 2013".

KW - 1β-Interleukin

KW - Gamma-aminobutyric acid

KW - Glutamate

KW - Hippocampal atrophy

KW - Hypothalamic-pituitary-adrenal hyperactivity

KW - Major depressive disorder

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84910650849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910650849&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2014.06.027

DO - 10.1016/j.yebeh.2014.06.027

M3 - Article

C2 - 25260238

AN - SCOPUS:84910650849

VL - 38

SP - 3

EP - 7

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -